Lupus & antiphospholipid syndrome
Nutritional, biochemical, and clinical determinants of hyperuricemia in systemic lupus erythematosus patients: Relationship with clinical and renal disease activity
Authors' conclusion
In conclusion, SLE patients with hyperuricemia presented a high risk of clinical and renal activity as well as worse cardiometabolic status.
Study context
- Population
- Systemic lupus erythematosus (SLE) patients and control subjects
- Participants
- 167 vs 195
- Exposure
- SLE patients with vs without hyperuricemia; SLE patients vs control subjects
- SLEn = 167
- Control subjects (CS)n = 195reference
- Outcome
- Nutritional, biochemical and cardiometabolic determinants of hyperuricemia and its relationship with clinical variables in SLE
Main finding
As reported in the abstract
Determinants of hyperuricemia in SLE (OR)
- Adequate protein intake: lower risk of hyperuricemia, OR
- 0.4; p = 0.04
- Adequate carbohydrate intake: lower risk of hyperuricemia, OR
- 0.2; p = 0.01
- Hyperuricemia: clinical activity, OR
- 2.2; p = 0.03
- Hyperuricemia: renal activity, OR
- 3.4; p < 0.01
- Hyperuricemia: triglycerides ≥150 mg/dL, OR
- 3.6; p < 0.01
- Hyperuricemia: hs-CRP ≥1 mg/L, OR
- 3.1; p < 0.01
- Hyperuricemia: Kannel score ≥3, OR
- 2.5; p = 0.02
- Hyperuricemia: BMI ≥25 kg/m², OR
- 2.2; p = 0.02
- HDL-C ≥40 mg/dL: lower risk of hyperuricemia, OR
- 0.2; p < 0.01
- Prednisone: high risk of hyperuricemia, OR
- 4.7; p < 0.001
- HCQ: lower risk of hyperuricemia, OR
- 0.4; p = 0.02
Observational data: associations, not effects.
Original publication
Nutritional, biochemical, and clinical determinants of hyperuricemia in systemic lupus erythematosus patients: Relationship with clinical and renal disease activity. Lupus. Published 23 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →